NVS -4.59 (-4.11%) $112.48 Price Target $118.13 Get XLV alerts: In 2023, 70% of revenue came from promoted brands, and 30% from established brands. Within promoted brands, the company divided revenue into four broad therapeutic areas: Cardiovascular, renal & metabolic, Immunology, Neuroscience, and Oncology. A notable strategic move by Novartis in 2023 was the spin-off of Sandoz. Sandoz is a producer of generics and biosimilars. This spin-off enables Novartis to focus on being what it calls a "pure-play inn ...

Investors were caught off guard by a decision on the research and development front. And yet, Novartis stock is down 4.5% as of 1:55 p.m. ET Thursday, according to data from S&P Global Market Intelligence. One red flag spoils an otherwise solid quarter Novartis is looking for more of the same in the near future. Its previous full-year projection for operating income growth in the low to mid teens was raised to an expectation of growth in the mid to high teens. That's a considerable increase for a company of ...

Operator Thank you. Your next question comes from the line of Mark Purcell from Morgan Stanley. Mark Purcell Yes, thank you very much for taking my question. Vas, your revenue aspiration is for mid-single-digit growth out to 2030, and now on a 2024 basis with about $66 billion. And when we look at consensus, it's about $53 billion at the moment before the results that were very strong today, so about a $13 billion gap. So which growth drivers, in your opinion, does consensus underappreciate? And what are th ...

Novartis ADRs slid 3.5% to $107.83 as of 10:13 a.m. ET Thursday. They are up about 7% this year. Do you have a news tip for Investopedia reporters? Please email us at tips@investopedia.com Key Takeaways Novartis posted second-quarter net sales and adjusted profit that beat analysts' expectations. The drugmaker upped its full-year core operating income outlook for the second time in as many quarters. Novartis now expects fiscal 2024 core operating income to grow by a mid- to high-teen-percentage rate, up fro ...

Shares of Novartis have risen 10.7% year to date compared with the industry's growth of 23.4%. In October 2023, Novartis completed the spin-off of its generic and biosimilar unit, Sandoz, following which the latter became an independent company. The results of the Sandoz division and selected portions of corporate activities attributable to the Sandoz business are reported as discontinued operations. Cosentyx's sales (psoriasis, spondylitis and arthritis) increased 22% to $1.5 billion, which beat the Zacks ...

Fabhalta (iptacopan) Lutathera (lutetium Lu 177 dotatate) In line with our strategic focus on oncology, Novartis acquired >90% of the total share capital of MorphoSys AG, adding to our pipeline pelabresib, a late-stage investigational BET inhibitor for myelofibrosis, and tulmimetostat, an early-stage investigational dual inhibitor of EZH2 and EZH1 for solid tumors or lymphomas. Coartem (artemetherlumefantrine) Net income was USD 3.2 billion (+43%, +49% cc), mainly driven by higher operating income. EPS was ...

Seeking Alpha, TradingView As I covered in the first quarter earnings review article, the reported numbers should remain unfavorable due to the spinoff of the generic unit Sandoz last year. We should look at the adjusted numbers of the remaining core business (continuing operations), which continue to look strong. Seeking Alpha The key performance drivers will be the innovative growth products, and Entresto: The core EPS consensus is $1.85, up 0.9% Y/Y in reported numbers, and an 11% increase if we look at ...

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days. Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ...

C3G Disease Overview - C3G is a rare kidney disease with no specifically approved therapies, leading most patients to progress to kidney failure requiring dialysis or transplant [8] - Current treatments are complex and burdensome, often involving combinations of antihypertensive agents, SGLT2 inhibitors, corticosteroids, and immunosuppressive agents [9] - Nephrologists adjust treatment approaches based on eGFR decline and proteinuria levels, with SGLT2 inhibitor use increasing year-over-year [9] Physician Perspectives and Challenges - 148 nephrologists across EU5 countries emphasize the urgent need for effective C3G treatments and the importance of early intervention [1] - Less than half of EU5 nephrologists feel confident in achieving target proteinuria levels with current treatments [2] - Over 75% of audited C3G patients are expected to progress to end-stage renal disease within the next decade [2] Emerging Treatment Landscape - Promising new treatments in development include Novartis' Fabhalta (iptacopan) and Apellis' Empaveli (pegcetacoplan) [3] - Phase III APPEAR-C3G study showed Fabhalta plus supportive care achieved a 35.1% reduction in proteinuria at 6 months compared to placebo [10] - Additional pipeline assets from Q32 Bio, Omeros, and others offer hope for better C3G management [3] Market Research and Insights - Spherix's Patient Chart Dynamix™ service analyzes real patient management patterns and treatment decision drivers [4] - Market Dynamix™ provides analysis of markets expected to experience paradigm shifts in 3-5 years, including C3G [12] - Spherix monitors specialty markets across multiple therapeutic areas through its extensive Physician Community [13]